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Abstract
Background: Multiple Sclerosis (MS) causes not only somatic, but also cognitive impairment
regardless of the patients' age or the course of the disease. The Brief International Cognitive 
Assessment for MS (BICAMS) test, published in 2011, is a short cognitive questionnaire: a 
fast, reliable, sensitive and specific tool for the evaluation of the patients' cognitive state.
Objectives: Our primary objective was to assess the validity of the Hungarian version of the 
BICAMS test. Our secondary objective was to evaluate the impact of the cognitive 
impairment on the patient's quality of life and fatigue’s impact on the patients’ cognitive state.
Methods: 65 RR-MS patients and 65 age, sex and education matched healthy control (HC) 
subjects completed the test and were retested after 3 weeks. The patients also completed the 
MS Quality of Life 54 (MSQoL54) and the Fatigue Impact Scale (FIS) assessments. Group  
differences were calculated by paired sample T-tests. The test-retest reliability was measured 
by intraclass correlation coefficients. To analyze the difference between the test-retest 
performances of the two groups we used two-way repeated measures ANOVA where the 
BICAMS battery was the single composite outcome and one-way repeated measures 
ANOVA. To assess the impact of the cognitive decline on the patients' quality of life and 
fatigue’s impact on the cognitive state, we examined the correlations between results in the 
BICAMS and the MSQoL54 and FIS.
Results: We found significant difference (p≤0.001, p=0.017 in the first CVLT-II assessment) 
between MS patients and members of the HC group in all four evaluated parameters of 
BICAMS test in both sessions. The correlation coefficients were very strong between the tests
and retests (r>0.8; p<0.001; r=0.678, p<0.001 between the CVLT-II assessments). We found 
that the HC group performed significantly (p=0.020) better in the retest sessions as compared 
to their original performance than the patients did and this difference is solely due to the 
difference between the CVLT-II performances. We have found significant negative 
correlation between the patients' cognitive function and the fatigue score (r<-0.3, p<0.05). 
Seven of the MSQoL-54 subscales correlated with the BICAMS performance (r>0.3; p<0.05).
Conclusions: The Hungarian version of the BICAMS test is a valid and reliable method for 
the evaluation of MS patients' cognitive function. It seems that because of the short retest 
period, the members of the HC group remembered the CVLT-II words thus performed better 
than the patients did. Also apparently fatigue can have a negative impact on the patients’ 
cognitive state, and cognitive impairment could worsen the patients' quality of life.
Keywords: Multiple Sclerosis, Cognition, Validation, BICAMS, Fatigue, Health-related 
quality of life
Introduction
Multiple Sclerosis (MS) is a chronic, autoimmune and neurodegenerative disease of the 
central nervous system (CNS) which can cause a wide range of symptoms, including decline 
in the cognitive functions. The prevalence of cognitive impairment is found to be high in MS 
patients, ranging from 43-70 % . It can occur at all stages of the disease, even in clinically and
radiologically isolated syndromes (CIS and RIS) and can affect any patient regardless of age 
and sex .
Cognitive impairment is not global in MS; it most commonly affects three aspects: 
information processing speed being the most vulnerable aspect followed by episodic memory 
and executive function . The degree of the impairment can be mild and patients may not be 
fully aware of it . Also patients often report the cognitive decline unreliably as depression can 
cause over-reporting, while metamemory-impairment can lead to underestimation .
There is significant correlation between the progression of cognitive impairment and the rate 
of brain atrophy according to studies involving magnetic resonance imaging (MRI) in the 
evaluation . Also the presence of cortical lesions is associated with the decline in cognition .
Fatigue is a very common symptom of MS; studies indicate its prevalence to be 76-92% . 
Many patients report it to be the worst or one of the worst symptoms of the disease . Studies 
show significant correlations between the Expanded Disability Status Scale (EDSS) score and
fatigue’s presence and severity . Hypothetically fatigue can have a negative impact on the 
patients’ cognitive abilities, though recent studies did not find significant correlation between 
cognitive status and subjective fatigue . 
Health-related quality of life (HRQoL) by definition represents “the functional effect of an 
illness and its consequent therapy upon a patient, as perceived by the patient” . In the different
clinical courses of MS differences were found between the subgroups: quality of life was 
lower of the patients with longer disease duration and with a more severe and progressive 
clinical course . Cognitive impairment is an extremely important aspect of HRQoL as it is an 
important determinant of employment status and social costs . Also cognitive deficit impairs 
the patients’ activities in everyday life by reducing physical independence, driving ability, 
coping, symptom management and rehabilitation potential . It was found that MS patients are 
more concerned about their mental health than physical disability . 
The importance of assessing the cognitive status of patients with MS cannot be overstated. 
There are several psychometric assessment batteries available, the most frequently utilized are
the Brief Repeatable Battery of Neuropsychological tests (BRB-N)  and the Minimal 
Assessment of Cognitive Function in MS (MACFIMS) . The problem with these batteries are 
that they are time-consuming (BRB-N requires 45 minutes, MACFIMS approximately 90 
minutes to perform) and they require special expertise which is not routinely available in 
many places . For this reason a specialized battery has been recommended by the BICAMS 
committee, which is short, simple to administer and to score, and does not require any special 
equipment or training but is also highly sensitive .
Objectives
The objectives of our study were:
1. The cross-cultural validation of the BICAMS battery to Hungarian language.
2. Measuring the impact of cognitive impairment on the patients’ quality of life and 
fatigue’s effect on the patients’ cognitive state by assessing the correlations between 
BICAMS performance with the Hungarian versions of both the FIS  and MSQoL-54  
batteries.
Patients and methods
Methods
The BICAMS battery comprises of 3 individual tests: the Symbol Digit Modalities Test 
(SDMT), the first five recall trials of the California Verbal Learning Test II. (CVLT-II) and 
the first three recall trials of the Brief Visuospatial Memory Test Revised (BVMT-R) .
The SDMT measures the information processing speed of the participant. It is a sheet of nine 
symbols in pseudo-randomized lines, each paired with a digit in a key at the top of the sheet. 
After a short practice, the patients have to pair as many of the symbols with the digits as they 
can in 90 seconds. There is both a written and an oral version of the test. During the written 
version the patients are given the sheet and they have to write the correct digits on the paper, 
whereas in the oral version both the administrator and the patient are given one sheet each and
the patient is required to say the correct number out loudly while the administrator writes it 
down. Both versions of SDMT were administered for the capability to assess patients with 
impaired motor functions. The dependent variable is the total number of correct responses .
The CVLT-II is a tool for measuring verbal learning. The first five recall trials of CVLT-II are
comprised of a list of 16 words clustered into 4 semantic groups. During administration the 
administrator reads the list aloud at the approximate speed of 1 word/second. The patients 
have to recall as many of the words as they can and repeat them back to the administrator in 
arbitrary order, who writes them down. There is no time limit for this test. The dependent 
variable is the total number of correct words recalled during the five trials . 
The BVMT-R is the measure of visual memory. It is administered by giving the patients a 
blank sheet of paper divided into six equal parts and a pencil. Then the administrator shows 
them a matrix of 6 abstract designs for 10 seconds which the patients are required to 
reproduce on the blank sheet of paper as accurately as they can. Each design receives a score 
of 0, 1, or 2 based on accuracy and location criteria. There is no time limit for this test. The 
dependent variable was the total points received for the reproduced designs during the three 
trials .
The validation was conducted per the international standards given by Benedict et al. in 2012 .
As the first step, the CVLT-II list of words were translated and retranslated from English to 
Hungarian and vice versa respectively (the other two tests did not require translation due to 
their nature). In the second step, the relevant parts of the tests manuals were translated into 
Hungarian. The third step was the testing, and after 3 weeks, the retesting of the patients and 
members of the HC group matched in age, sex and years of education between December 
2013 and March 2014.
Also for the assessment of the correlations between the cognitive status and fatigue and the 
cognitive status and quality of life, all 65 patients had completed the Hungarian versions of 
the Fatigue Impact Scale (FIS) and the Multiple Sclerosis Quality of Life-54 (MSQoL54) 
batteries during that period. 
The FIS battery is comprised of 40 questions, divided into 3 subscales: 20 questions related to
social functions, 10 questions to physical functions and 10 questions to cognitive functions. 
Each question is marked from 0 (minimal degree) to 4 (severe degree) points .
MSQoL-54 is a battery of 54 questions which can be divided into numerous subscales 
representing many aspects of life: physical health, emotional well-being, role limitations due 
to physical problems, role limitations due to emotional problems, pain, energy, health 
perceptions, social function, cognitive function, health distress, sexual function, satisfaction 
with sexual function, change in health and overall quality of life. From these subscales, two 
composite scores can be derived: the physical health composite score and the mental health 
composite score  
We used the first BICAMS tests of the patients for comparison with FIS and MSQoL-54.
Patients and the HC group
We recruited 65 patients treated at the Multiple Sclerosis Outpatient’s Unit of the Department 
of Neurology of the University of Szeged and 65 healthy controls matched in age, sex and 
years of education for the validation process. The patients were recruited cross-sectionally, 
there was no pre-selection applied for cognitive impairment. Of the patients 16 were men, 49 
women; 31 of the patients studied ≤12 years, and 34 of them studied for at least 13 years. 
Their average age was 41.9 (± 8.9) years, the average age for disease onset was 29.8 (± 9.9) 
years and the average time from MS onset was 11.1 (±7.6) years. Their average EDSS score 
was 2.5 (±1.8). Of the 65 members of the HC group, 16 were men and 49 women; 31 of them 
studied ≤12 years, and 34 of them studied for at least 13 years. Their average age was 40.9 (± 
11.8) years.
We have included patients and healthy control individuals aged between 18-65 years. Their 
first language is Hungarian, and all the patients were diagnosed with the relapsing-remitting 
(R-R) course of the disease by McDonald’s criteria. All patients were in remission during the 
evaluation and their EDSS score ranged from 0-6.5. 
We have excluded patients suffering from CIS, secondary or primary progressive course of 
the disease in order to work with a homogenous population for statistical reasons. As 
progressive MS patients only total up to 20% of the population in Hungary , their numbers 
would not have been representative in a patient pool of 65. We also excluded patients 
undergoing acute infection or an acute relapse. It was observed that psychiatric diseases, 
mood disorders and personality disorders have a fairly large co-incidence with MS (the 
leading co-morbidity being depression) . As it is also established that these disorders can 
cause cognitive impairment , any patient or possible member of the HC group with diagnosed 
psychiatric, mood or personality disorder was excluded from our study. Also it was published 
recently that chronic alcohol abuse has a high prevalence among MS patients (14.8%) . 
Chronic alcoholism severely impairs the cognitive state , therefore any patients or possible 
member of the HC group, with history of chronic alcohol abuse, were excluded from 
participation in the validation process.
Statistical analysis
To measure the differences between the patients and members of the HC group we used 
paired sample T-tests. Assessing the test-retest reliability and the correlation between 
BICAMS and FIS and BICAMS and MSQoL54 were done by calculating the Pearson 
correlation coefficients. To analyze the difference between the test and retest performances of 
the patients and the HC group we used two-way repeated measures ANOVA with the result of
the BICAMS battery being a composite outcome and one-way repeated measures ANOVA to 
assess the differences by the battery-types that compose the BICAMS battery. Statistical 
analysis was done by using SPSS 21.0 software.
The assessment was authorized by the Ethics Committee of the University of Szeged 
(authorization number 127/2013).
Results
BICAMS validity
Both the patients and the HC group consisted of 16 men and 49 women, in both groups 31 
individuals studied ≤12 years, and 34 of them studied for at least 13 years. There was no 
difference between the mean age of the two groups (p=0.610).
Table 1 shows the group data and the differences between the patients’ and HC groups’ raw 
scores in all 4 trials and during the retests as well. It is apparent that the MS patients 
performed significantly worse in all trials than the members of the HC group (p≤0.001 in all 
tests other than the first CVLT-II; p=0.017 in the first CVLT-II). 
We identified 34 of the 65 (52.3%) patients with cognitive impairment, by the proposed 
criterion of “one or more abnormal tests”. As no validated threshold of cognitive impairment 
for BICAMS was available, we used the thresholds given in the manuals of the separate tests 
(SDMT, BVMT-R, CVLT-II). 
We have found that 26 patients (40.0%) had abnormal SDMT scores, 24 (36.9%) patients had 
abnormal BVMT-R tests and 9 (13.8%) patients’ performance was abnormal during CVLT-II 
testing. Per the “one or more abnormal tests” criterion we found 15 patients (23.0%) with one 
abnormal test, 13 patients (20.1%) with two abnormal tests and 6 patients (9.2%) with three 
abnormal tests. 
We identified 9 (13.8%) patients with abnormal score only in their SDMT performance, 6 
(9.2%) only in their BVMT-R tests. We found no patient with sole CVLT-II abnormality. Ten
(15.5%) patients performed impaired in both the SDMT and the BVMT-R tests, 1 (1.5%) 
patient in both the SDMT and CVLT-II tests, 2 (3.1%) patients in both the BVMT-R and 
CVLT-II tests. 6 (9.2%) patients had abnormal scores in all three tests.
Table 1 - Group data comparing patients with multiple sclerosis and healthy controls
 
Raw score (±SD)
p
Patients HC group
SDMT written 44.31 (± 11.76) 54.88 (± 10.32) <0.001
SDMT written retest 49.38 (± 14.91) 62.31 (± 12.78) <0.001
BVMT-R 22.54 (± 8.54) 26.68 (± 5.56) 0.001
BVMT-R retest 26.89 (± 8.21) 31.81 (± 4.13) <0.001
SDMT oral 55.62 (± 15.48) 66.82 (± 12.44) <0.001
SDMT oral retest 59.40 (± 18.29) 72.84 (± 13.88) <0.001
CVLT-II. 55.37 (± 10.71) 59.03 (± 8.29) 0.017
CVLT-II. retest 61.77 (± 14.20) 70.58 (± 8.29) <0.001
SD, standard deviation; HC group, healthy control group; SDMT, Symbol Digit Modalities Test; CVLT-
II., California Verbal Learning Test II.; BVMT-R, Brief Visuospatial Memory Test Revised (BVMT-R)
Table 2 shows the correlation between the tests and the retests. Overall correlations are very 
strong (r>0.8 p<0.001; r=0.678; p<0.001 between the CVLT-II assessments). Regarding the 
performance of the patients and the HC group separately, the patients’ performance shows 
slightly higher values than the HC group, the biggest difference being in the CVLT-II test 
(r=0.743; p<0.001 in case of the patients, r=0.453; p<0.001 in case of the HC group).
Table 2 - Correlation coefficients between the tests and the retests
 
Overall Patients HC group
r p r p r p
SDMT written 0.874 <0.001 0.883 <0.001 0.796 <0.001
BVMT-R 0.864 <0.001 0.873 <0.001 0.805 <0.001
SDMT oral 0.830 <0.001 0.884 <0.001 0.664 <0.001
CVLT-II 0.678 <0.001 0.743 <0.001 0.453 <0.001
HC group, healthy control group; SDMT, Symbol Digit Modalities Test; CVLT-II., California Verbal 
Learning Test II.; BVMT-R, the Brief Visuospatial Memory Test Revised (BVMT-R)
We evaluated the difference between the patients’ and the HC group’s test-retest scores. 
There are greater differences between the test and the retest mean scores in the HC group than
between the patients’ scores (Table 1) and also the correlation between the tests and the 
retests are weaker within the HC group as was mentioned above (Table 2). 
We found significant difference between the patients’ and the HC group’s test-retest 
performances with a multivariable test where the result of the BICAMS battery was the single
composite outcome (p=0.020, Table 3). We also conducted multiple univariate tests sorting 
by the battery types and we found significant difference only in the CVLT-II performances 
(p=0.003, Table 4). Our model satisfied the assumption of sphericity (p>0.05). 
Table 3 – Multivariable test of the test-retest performances of the patients and HC group
Within subject effect p Observed power
Test-Retest and Patient-HC group 0.020* 0.790
HC group, healthy control group
*=Significant at the level of p<0.05
Table 4 – Univariate tests of the test-retest performances of the patients and HC group by battery types
Within subject effect Measure p Observed Power
Test-Retest and 
Patients-HC group
SDMT written 0.063 0.460
BVMT-R 0.313 0.171
SDMT oral 0.231 0.223
CVLT-II 0.003* 0.862
HC group, healthy control group; SDMT, Symbol Digit Modalities Test; CVLT-II., California Verbal 
Learning Test II.; BVMT-R, the Brief Visuospatial Memory Test Revised (BVMT-R)
*=Significant at the level of p<0.05
Correlations with fatigue and quality of life
We assessed the impact of subjective fatigue on the patients’ cognitive status by examining 
the correlations between their scores during the BICAMS battery and the scores of the FIS 
battery. 
We have found significant negative correlations (r<-0.3; p<0.05) between the patients’ overall
subjective fatigue scores and their cognitive performance in all parts of BICAMS, shown in 
Table 5. Though we made the observation, that regarding the subscales, the decline in the 
cognitive functions measured by BICAMS correlated best with the physical dimension 
subscale of FIS, then with the social subscale; while considering the cognitive subscale of FIS
we only found significant correlation with the oral SDMT and the CVLT-II performance.
Table 5 - Correlations between the FIS battery and its subscales with the parts of the BICAMS battery
 
Total points Cognitive dimension Physical dimension Social dimension
r p r p r p r p
SDMT written -0.346 0.008* -0.248 0.052 -0.406 0,001* -0.293 0,023*
BVMT-R -0.322 0.014* -0.247 0.053 -0.351 0,006* -0.255 0,049*
SDMT oral -0.359 0.006* -0.279 0.028* -0.411 <0,001* -0.239 0,065
CVLT-II. -0.301 0.022* -0.311 0.014* -0.302 0,018*  -0.316 0,014*
SDMT, Symbol Digit Modalities Test; CVLT-II., California Verbal Learning Test II.; BVMT-R, the Brief 
Visuospatial Memory Test Revised (BVMT-R)
*=Significant at the level of p<0.05
Assessment of the impact of cognitive impairment on the patients’ quality of life was done by 
examining the correlations between the performance in BICAMS battery and the scores in 
MSQoL-54. 
Table 6 - Correlations between performance in BICAMS battery and score in MSQoL-54 battery
MSQoL-54 scale SDMT written BVMT-R SDMT oral CVLT-IIr p r p r p r p
Physical 
functioning 0.440 <0.001 0.279 0.025 0.427 0.001 0.252 0.045
Cognitive 
functioning 0.300 0.015 0.298 0.016 0.302 0.014 0.325 0.008
Social 
functioning 0.252 0.043 0.326 0.008 0.331 0.007 0.334 0.005
General health 0.448 <0.001 0.396 0.001 0.441 <0.001 0.375 0.002
Overall quality 
of life 0.251 0.045 0.273 0.029 0.280 0.025 0.239 0.057
Sexual 
functioning 0.445 <0.001 0.332 0.010 0.461 <0.001 0.402 0.002
Satisfaction with 
sexual 
functioning
0.391 0.002 0.337 0.009 0.402 0.002 0.376 0.003
SDMT, Symbol Digit Modalities Test; CVLT-II., California Verbal Learning Test II.; BVMT-R, the Brief 
Visuospatial Memory Test Revised (BVMT-R)
Table 6 shows that cognitive impairment correlates significantly with 7 subsequent subscales: 
physical functioning, social and cognitive functioning, general health scale, overall 
quality of life and sexual performance and satisfaction with sexual performance.
Discussion
Cognitive impairment is a frequent yet not routinely assessed symptom of multiple sclerosis . 
A special committee of neurologists and neuropsychologists has recommended the simple yet 
highly reliable BICAMS for assessing cognitive impairment in patients with MS . Our 
validation process found significant differences (p≤0.001 in all tests other than the first 
CVLT-II; p=0.017 in the first CVLT-II) between the patients’ scores and the scores of the 
members of the HC group, also it has established strong correlations (r>0.67, p<0,001) when 
assessing the test-retest reliability. With this method we have shown that the Hungarian 
version of the BICAMS battery is just as valid as the original English  and recently validated 
Czech counterparts .
We have also evaluated the possible reason behind the slightly weaker CVLT-II correlation 
and the differences between the test-retest scores and the correlation coefficients of the 
patients and the HC group. We have found that the members of the HC group performed 
significantly (p=0.020) better at the retest period comparing to their original performance than
the patients did. This difference can seemingly solely be attributed to their CVLT-II 
(p=0.003) performances, though we found a borderline significance of the within-subject 
effect of the written SDMT scores (p=0.063) with a relatively lower observed power value 
(OP=0.460), which could very well mean that the lack of power is responsible for the lack of 
true significance. This could imply that the difference may be attributed partly to the SDMT 
performances as well, yet the only true significant difference was between the two groups 
CVLT-II scores. The reason can very well be the short interval between re-administering and 
the use of the same form of the CVLT-II both times , hence the examinees remembered the 
words from the previous examination three weeks before. Another important factor can be the
lack of novelty effect during the second administration, thus the anxiety of a new situation did
not interfere with the performance of the examinees . As the control group consisted of 
healthy individuals while more than half (52%) of the patients had cognitive impairment it is a
possibility that - despite the relative better performance of the MS patients during the retest 
period comparing to their original scores – cognitive impairment prevented them from 
improving as much as the healthy individuals did, but this cannot be stated without further 
assessment. 
Studies estimate the prevalence of cognitive impairment to be 43-70% among patients with 
MS . Recently, Dusankova et al. found the prevalence of cognitive impairment in the Czech 
MS population to be 55% while validating the Czech version of MACFIMS and BICAMS . 
As there was no consensus yet established, they have proposed the using of “one or more 
abnormal tests” for identifying cognitive deficit . By using this proposed criterion, we have 
found that 52% of our patients had cognitive impairment – similarly to their findings and 
other studies in the literature . 
A relationship between fatigue and cognitive decline has been proposed, but there haven’t 
been many studies dedicated to it. Patients often report that fatigue impairs their cognitive 
abilities , yet most of the studies dedicated to assess the relation between self-reported fatigue 
and objective cognitive performance have failed to find any significant correlation between 
the two . However Andreasen et al. did report that fatigued MS patients’ information 
processing speed was slower than non-fatigued patients’. Our findings may imply similarly as
Andreasen et al., that fatigue can have a negative impact on the patients’ cognitive state: 
overall FIS points showed significant negative correlations with the patients’ BICAMS 
performance (r<-0.3; p<0.05), and the strongest correlation was shown with the SDMT 
performances of the patients. Yet to draw any clear conclusions, this should be investigated 
further on a larger population of patients by multivariable models as age, disability, disease 
duration and other factors could be (at least partially) responsible for the correlation. 
Regarding the subscales of FIS, the physical subscale showed the strongest correlation with 
cognitive status and the cognitive subscale only showed significant correlation with the oral 
version of SDMT and the CVLT-II tests. This could imply that the physical aspect of fatigue 
could be primarily responsible for the worsening, but as said above, clear conclusions cannot 
be drawn without further investigations. As was mentioned, it is important that our patient 
pool was comprised of only 65 patients, so evaluation on a larger population might yield 
different results. Also we only assessed patients of the relapsing-remitting disease course and 
it has been suggested that cognitive impairment might be a corresponding marker of the 
progressive component of MS , so future evaluations should take this into consideration.
Multiple Sclerosis affects the patients’ quality of life on several levels, and the impact of 
cognitive impairment on the patients’ HRQoL is a highly important problem. As MS patients 
have a high prevalence of cognitive dysfunction, and it was shown that MS patients are more 
concerned about their mental status than their physical disability, the correlation between their
cognitive performance and their self-reported quality of life becomes a very important 
question. Several studies found that the decline in cognitive status worsens the patients QoL . 
Benito-León et al. reported that during their evaluation, QoL significantly correlated with 
cognitive status, depression and anxiety - which means that the worse the cognitive 
performance is, the lower the patient’s QoL is . Interestingly however during the COGIMUS 
study, they only found significant difference between cognitively impaired and cognitively 
healthy MS patients in two subscales of MSQoL-54 and the cognitively impaired patients 
reported better QoL  . Also Kenealy et al. observed that MS patients with impaired 
autobiographical memory reported significantly better HRQoL . However it is known that 
high cognitive reserve (which was the case in COGIMUS as main IQ was over 102) protects 
from cognitive decline and may suggest better coping mechanisms  which can lead to better 
perception of QoL. Kenealy et al. concluded that patients with impaired autobiographical 
memory may not be able to validly compare their past QoL to the present which can resulted 
in these findings.  
Our findings yielded similar results as the studies mentioned earlier . Seven subscales of 
MSQoL-54 showed significant correlation with scores on the BICAMS battery – cognitive, 
physical and social functioning subscales, overall quality of life and general health subscales, 
the sexual function and the satisfaction with sexual function subscales showed significant r 
levels. This means that cognitive impairment may be responsible for a serious negative impact
on the patients’ QoL and not just in some aspects of life, but in most. Though, as well as 
fatigue’s impact on cognition, this should be evaluated on a larger patient pool and more 
variables (demographic, co-morbidity etc.) should be considered.
As a conclusion we can state that the Hungarian version of BICAMS, which is the third 
version to be validated in Europe, is a short, easily administered yet highly sensitive and 
specific tool for clinical evaluation of the cognitive impairment in MS. Also our findings 
suggest that fatigue can have a negative impact on the patients’ cognitive state and that the 
decline in cognition could damage the patients’ quality of life. Therefore the assessment and 
the follow-up of the patients’ cognitive status should be as much a priority as the evaluation 
of somatic manifestations of the disease.
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